Furthermore, taselisib for breast cancer (NCT02340221), duvelisib for chronic lymphocytic leukemia (NCT02004522), and ipatasertib for advanced-stage breast cancer (NCT03800836) are undergoing phase III clinical trials advocating the potential use of mTOR and PI3K inhibitor for therapeutic interventions [37,38,39]. Here, MTOR is linked to breast cancer.